TY - JOUR
T1 - Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer
AU - Zhu, Yimin
AU - Lai, Maode
AU - Yang, Hushan
AU - Lin, Jie
AU - Huang, Maosheng
AU - Grossman, H. Barton
AU - Dinney, Colin P.
AU - Wu, Xifeng
N1 - Funding Information:
We thank Dr Angelique Siy for her scientific editing. This work was supported by National Cancer Institute grants CA74880, CA91846 and CA110928.
PY - 2007/3
Y1 - 2007/3
N2 - Xeroderma pigmentosum complementation group C (XPC) is responsible for DNA damage recognition in the initial steps of the nucleotide excision repair pathway. Genetic variations in the XPC gene may be associated with impaired protein function and increased risk for bladder cancer. To elucidate the roles of common polymorphisms of XPC in the etiology of bladder cancer, we conducted a hospital-based case-control study including 578 Caucasian incident bladder cancer patients and 578 age- and gender-matched Caucasian controls. We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C→T), PAT (-/+) and Lys939Gln (A→C), with the risk of bladder cancer. No significant association was found for any individual polymorphism. However, the C-C and T-A (indicated as in the order of Ala499Val-PAT-Lys939Gln) haplotypes were associated with reduced bladder cancer risks, with odds ratios (ORs) of 0.51 [95% confidence interval (CI) = 0.34-0.78] and 0.79 (0.60-1.04), respectively. The protective effects were more evident in men, people younger than 59 years, and ever-smokers. We also found that four diplotypes were significantly associated with reduced bladder cancer risk, with ORs (and 95% CIs) of 0.53 (0.34-0.82) for C-A/T-A, 0.48 (0.27-0.84) for C-A/C-C, 0.18 (0.053-0.60) for C-C/C-C and 0.57 (0.36-0.90) for C+C/C+C. These results suggest that sequence variants in the XPC gene might modulate the risk of bladder cancer.
AB - Xeroderma pigmentosum complementation group C (XPC) is responsible for DNA damage recognition in the initial steps of the nucleotide excision repair pathway. Genetic variations in the XPC gene may be associated with impaired protein function and increased risk for bladder cancer. To elucidate the roles of common polymorphisms of XPC in the etiology of bladder cancer, we conducted a hospital-based case-control study including 578 Caucasian incident bladder cancer patients and 578 age- and gender-matched Caucasian controls. We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C→T), PAT (-/+) and Lys939Gln (A→C), with the risk of bladder cancer. No significant association was found for any individual polymorphism. However, the C-C and T-A (indicated as in the order of Ala499Val-PAT-Lys939Gln) haplotypes were associated with reduced bladder cancer risks, with odds ratios (ORs) of 0.51 [95% confidence interval (CI) = 0.34-0.78] and 0.79 (0.60-1.04), respectively. The protective effects were more evident in men, people younger than 59 years, and ever-smokers. We also found that four diplotypes were significantly associated with reduced bladder cancer risk, with ORs (and 95% CIs) of 0.53 (0.34-0.82) for C-A/T-A, 0.48 (0.27-0.84) for C-A/C-C, 0.18 (0.053-0.60) for C-C/C-C and 0.57 (0.36-0.90) for C+C/C+C. These results suggest that sequence variants in the XPC gene might modulate the risk of bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=34047127455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34047127455&partnerID=8YFLogxK
U2 - 10.1093/carcin/bgl201
DO - 10.1093/carcin/bgl201
M3 - Article
C2 - 17052994
AN - SCOPUS:34047127455
SN - 0143-3334
VL - 28
SP - 698
EP - 703
JO - Carcinogenesis
JF - Carcinogenesis
IS - 3
ER -